scholarly journals Characteristics of Geographical Spread and Temporal Accumulation of the 2009 Influenza A (H1N1) Epidemic in Japan Based on National Surveillance Data

2014 ◽  
Vol 67 (5) ◽  
pp. 368-373 ◽  
Author(s):  
Akiko Ohta ◽  
Shuji Hashimoto ◽  
Yoshitaka Murakami ◽  
Miyuki Kawado ◽  
Kiyosu Taniguchi ◽  
...  
Keyword(s):  
Influenza A ◽  
Surveillance Data ◽  
National Surveillance ◽  
Geographical Spread ◽  
Influenza A H1n1 ◽  
Temporal Accumulation

Modeling the geographical spread of influenza A(H1N1): the case of Mexico

2013 ◽  
Vol 7 ◽  
pp. 2143-2176
Author(s):  
Rafael A. Barrio ◽  
Carmen Varea ◽  
Tzipe Govezensky ◽  
Marco V. Jose
Keyword(s):  
Influenza A ◽  
Geographical Spread ◽  
Influenza A H1n1

scholarly journals Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010–2015

2016 ◽  
Vol 64 (3) ◽  
pp. 364-367 ◽  
Author(s):  
Grace D Appiah ◽  
Sandra S Chaves ◽  
Pam D Kirley ◽  
Lisa Miller ◽  
James Meek ◽  
...  
Keyword(s):  
Influenza A ◽  
Antiviral Treatment ◽  
Population Based ◽  
Hospitalized Patients ◽  
Surveillance Data ◽  
Hospitalized Children ◽  
Influenza A H1n1

Abstract Using population-based surveillance data, we analyzed antiviral treatment among hospitalized patients with laboratory-confirmed influenza. Treatment increased after the influenza A(H1N1) 2009 pandemic from 72% in 2010–2011 to 89% in 2014–2015 (P < .001). Overall, treatment was higher in adults (86%) than in children (72%); only 56% of cases received antivirals on the day of admission.

scholarly journals Occurrence and spread of influenza A(H1N1)pdm09 virus infection in Norwegian pig herds based on active serosurveillance from 2010 to 2014

2016 ◽  
Vol 144 (15) ◽  
pp. 3148-3165 ◽  
Author(s):  
C. ER ◽  
E. SKJERVE ◽  
E. BRUN ◽  
T. FRAMSTAD ◽  
B. LIUM
Keyword(s):  
Virus Infection ◽  
Confidence Interval ◽  
Influenza A Virus ◽  
Influenza A ◽  
Haemagglutination Inhibition ◽  
Herd Size ◽  
Surveillance Data ◽  
Blood Samples ◽  
Pdm09 Virus ◽  
Influenza A H1n1

SUMMARYThe incursion of influenza A(H1N1)pdm09 virus was detected by Norway's active serosurveillance of its pig population in 2009. Since then, surveillance data from 2010 to 2014 revealed that 54% of 5643 herd tests involving 1567 pig herds and 28% of 23 036 blood samples screened positive for antibodies against influenza A virus. Positive herds were confirmed to have influenza A(H1N1)pdm09 virus infection by haemagglutination inhibition test. In 50% of positive herd tests, ⩾60% of the sampled pigs in each herd had antibodies against influenza A(H1N1)pdm09 virus. This within-herd animal seroprevalence did not vary for type of production, herd size or year of test. The overall running mean of national herd seroprevalence, and annual herd incidence risks fluctuated narrowly around the means of 45% and 32%, respectively, with the highest levels recorded in the three densest pig-producing counties. The probability of a herd being seropositive varied in the five production classes, which were sow pools, multiplier herds, conventional sow herds, nucleus herds, and fattening herds in descending order of likelihood. Large herds were more likely to be seropositive. Seropositive herds were highly likely to be seropositive the following year. The study shows that influenza A(H1N1)pdm09 virus is established in the Norwegian pig population with recurrent and new herd infections every year with the national herd seroprevalence in 2014 hovering at around 43% (95% confidence interval 40–46%).

scholarly journals Exploring National Surveillance for Health-Related Workplace Absenteeism: Lessons Learned From the 2009 Influenza A Pandemic

2013 ◽  
Vol 7 (2) ◽  
pp. 160-166 ◽  
Author(s):  
Matthew R. Groenewold ◽  
Doris L. Konicki ◽  
Sara E. Luckhaupt ◽  
Ahmed Gomaa ◽  
Lisa M. Koonin
Keyword(s):  
Influenza A ◽  
Population Based ◽  
Lessons Learned ◽  
Full Time ◽  
National Surveillance ◽  
Convenience Sample ◽  
Preparedness Planning ◽  
Influenza A H1n1 ◽  
Health Related ◽  
Nationally Representative

AbstractBackgroundDuring the 2009 influenza A (H1N1) virus pandemic, the Centers for Disease Control and Prevention did a pilot study to test the feasibility of using national surveillance of workplace absenteeism to assess the pandemic's impact on the workplace to plan for preparedness and continuity of operations and to contribute to health awareness during the emergency response.MethodsPopulation-based and sentinel worksite approaches were used. Monthly measures of the 1-week prevalence of health-related absenteeism among full-time workers were estimated using nationally representative data from the Current Population Survey. Enhanced passive surveillance of absenteeism was conducted using weekly data from a convenience sample of sentinel worksites.ResultsNationally, the pandemic's impact on workplace absenteeism was small. Estimates of 1-week absenteeism prevalence did not exceed 3.7%. However, peak workplace absenteeism was correlated with the highest occurrence of both influenza-like illness and influenza-positive laboratory tests.ConclusionsSystems for monitoring workplace absenteeism should be included in pandemic preparedness planning. (Disaster Med Public Health Preparedness. 2013;0:1–7)

scholarly journals Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively

2018 ◽  
Vol 23 (13) ◽  
Author(s):  
Cornelia Adlhoch ◽  
René Snacken ◽  
Angeliki Melidou ◽  
Silviu Ionescu ◽  
Pasi Penttinen ◽  
...  
Keyword(s):  
Eastern Europe ◽  
Influenza A ◽  
Surveillance Data ◽  
H3n2 Virus ◽  
Geographical Spread ◽  
B Virus ◽  
All Cause Mortality ◽  
Influenza Activity ◽  
A Current

We use surveillance data to describe influenza A and B virus circulation over two consecutive seasons with excess all-cause mortality in Europe, especially in people aged 60 years and older. Influenza A(H3N2) virus dominated in 2016/17 and B/Yamagata in 2017/18. The latter season was prolonged with positivity rates above 50% among sentinel detections for at least 12 weeks. With a current west–east geographical spread, high influenza activity might still be expected in eastern Europe.

School absenteeism surveillance data during the 2009 influenza A/H1N1 pandemic

2011 ◽  
Vol 4 (0) ◽  
Author(s):  
Kenneth Dufault ◽  
Elizabeth Daly ◽  
Susan Bascom ◽  
Christopher Taylor ◽  
Paul Lakevicius ◽  
...  
Keyword(s):  
Influenza A ◽  
Surveillance Data ◽  
H1n1 Pandemic ◽  
School Absenteeism ◽  
Influenza A H1n1

scholarly journals Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data

2014 ◽  
Vol 19 (36) ◽  
Author(s):  
T Harris ◽  
K Wong ◽  
L Stanford ◽  
J Fediurek ◽  
N Crowcroft ◽  
...  
Keyword(s):  
Young Adults ◽  
Influenza A ◽  
Health Information System ◽  
Vaccine Safety ◽  
Surveillance Data ◽  
H1n1 Vaccine ◽  
Safety Surveillance ◽  
Influenza A H1n1 ◽  
Post Marketing ◽  
Children And Young Adults

A vaccine safety signal and association between new onset of narcolepsy and AS03-adjuvanted pandemic influenza A(H1N1) vaccine (Pandemrix, GlaxoSmithKline) in children and young adults has been reported in several European countries. In Ontario, Canada, AS03-adjuvanted pandemic A(H1N1) vaccine (Arepanrix, GlaxoSmithKline) was the primary vaccine administered in 2009/10, with 4.8 million doses distributed. We assessed post-marketing safety surveillance data by extracting adverse events following immunisation (AEFIs) associated with this vaccine from the integrated Public Health Information System. Reports were screened for key terms related to narcolepsy and further limited to children and young adults four to 29 years of age. Of 1,604 AEFIs reported in Ontario, 53 reports met the search criteria. Individual assessment by a nurse consultant for additional context suggestive of narcolepsy yielded five reports for secondary medical review. None of the five reports proved consistent with a possible narcolepsy diagnosis based on the available information. We present the first post-marketing assessment from Canada of narcolepsy reports following receipt of Arepanix. Continued investigation of differences between Arepanrix and Pandemrix and subsequent risk of narcolepsy is indicated. In light of the limitations of passive surveillance to detect a signal in this instance, validation using other data sources is prudent.

Sign in / Sign up

Export Citation Format

Share Document